It has been proposed that the PD-L1 protein plays a critical role in the tumor microenvironment of DLBCL patients, leading to a more destructive clinical phenotype and a worse prognosis [118] that is not typical of GCB patients (e.g., suppression of T-cell proliferation and IFN-γ production by tumor-associated T cells). The gene discussed is CD274; the disease is neoplasm.